Talk:Butanilicaine

Learn more about this page

This is the talk page for discussing improvements to the Butanilicaine article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Chemicals Low‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals articles
Low	This article has been rated as Low-importance on the project's importance scale.

References

Latest comment: 7 years ago1 comment1 person in discussion

Following are a few sources I've found about butanilicaine.

Because of the lack of information online, I assume Sanofi-Aventis (now Sanofi) has stopped making it. The drug was marketed as Hostacain, under two forms: butanilicaine hydrochloride or butanilicaine phosphate (if someone could check this out, I would appreciate).

The drug has been used on humans, horses, and frogs. Butanilicaine phosphate was administered by injection, as a 0.5 to 3% solution. It was used in the making of stable solutions of hydrogenated ergotalkaloids (US patent US 4402949).

http://webbook.nist.gov/cgi/inchi/InChI%3D1S/C13H19ClN2O/c1-3-4-8-15-9-12(17)16-13-10(2)6-5-7-11(13)14/h5-7%2C15H%2C3-4%2C8-9H2%2C1-2H3%2C(H%2C16%2C17)

Drug Dosage in Renal Insufficiency, By G. Seyffart, p.83: https://books.google.ca/books?id=OavnCAAAQBAJ&pg=PA83&lpg=PA83&dq=Butanilicaine&source=bl&ots=lfjRlDa1jp&sig=xDyfC-sdC-gK7pvU_WpJS9NhZnQ&hl=en&sa=X&ved=0ahUKEwiP-pa04qvRAhUB4oMKHYvbAMoQ6AEIhgEwGg#v=onepage&q=Butanilicaine&f=false

2017 Equine Prohibited Substances List - Banned substances, Fédération Équestre Internationale (FEI): http://inside.fei.org/system/files/2017%20Banned%20Substances%20List_0.pdf

Literature References: Prepn: Häussler, Ther, Arzneim.-Forsch. 3, 609 (1953); GB 726080 (1955 to Polymer Corp.); GB 759744 (1956 to Cilag); GB 782971; G. Ehrhart et al., US 2912460 (1957, 1959 both to Hoechst); Epstein, Kaminsky, J. Am. Chem. Soc. 80, 1892 (1958). Structure activity study: P. P. Koelzer, K. H. Wehr, Arzneim.-Forsch. 8, 181 (1958).

http://www.xiuzhengrd.com/clark/current/clk0256.htm

Effects on peripheral nerve function

H. Gerhard Vogel, by Wolfgang H. Vogel — Preceding unsigned comment added by Enigma55 (talk • contribs) 20:19, 5 January 2017 (UTC)Reply

Add topic